A Study of LY3209590 in Participants With Type 2 Diabetes

Inclusion Criteria:

- Participants with Type 2 Diabetes Mellitus (T2DM) for at least 1 year

- Have a glycated hemoglobin (HbA1c) greater than or equal to (≥) 7.0 percent (%) to
less than or equal to (≤) 10.5% at screening

- Have had no episodes of severe hypoglycemia in the past 6 months

- Are on stable basal insulin (neutral protamine Hagedorn insulin suspension [NPH]
insulin, insulin glargine [U100 or U300], or insulin detemir) with or without
metformin, dipeptidyl peptidase IV (DPP-IV) inhibitors, sulfonylureas, and
sodium-glucose co-transporter 2 (SGLT-2) inhibitors, at a stable dose for at least 3
months before screening

Exclusion Criteria:

- Have significant lipohypertrophy in the target abdominal injection

- Have a history of renal impairment

- Have a history of deep vein thrombosis of the leg or repeated episodes of deep leg
vein thrombosis in first-degree relatives (parents, siblings, or children)

- Have proliferative retinopathy or maculopathy and/or severe neuropathy

- Any significant changes in insulin regimen and/or unstable blood glucose control
within the past 3 months prior to screening

- Require daily insulin treatment less than (<) 0.15 unit/kilogram (U/kg) per body
weight

- Are treated with a continuous subcutaneous insulin infusion (CSII) pump

- Currently receiving degludec insulin therapy, or have been treated with degludec
within the past 90 days